HC Wainwright Has Optimistic Opinion of ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at HC Wainwright raised their FY2026 EPS estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, November 4th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.91 for the year, up from their prior forecast of $0.68. HC Wainwright currently has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.72 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2026 earnings at $0.14 EPS, FY2028 earnings at $0.71 EPS, FY2029 earnings at $1.21 EPS and FY2030 earnings at $1.74 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The firm had revenue of $37.76 million for the quarter, compared to the consensus estimate of $37.08 million. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%.

Several other analysts have also weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. Guggenheim dropped their price objective on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Friday, August 7th. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. BTIG Research reduced their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Finally, Citizens Jmp raised their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and a consensus target price of $27.14.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock opened at $10.53 on Friday. The stock has a market cap of $625.31 million, a price-to-earnings ratio of 8.85 and a beta of 1.01. The stock has a 50 day moving average price of $11.07 and a 200-day moving average price of $10.77. Zevra Therapeutics has a one year low of $8.01 and a one year high of $15.03.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its position in Zevra Therapeutics by 15.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,835 shares of the company’s stock valued at $123,000 after buying an additional 1,427 shares during the period. Integrated Wealth Concepts LLC bought a new position in Zevra Therapeutics in the 2nd quarter worth about $28,000. Fulcrum Asset Management LLP bought a new position in Zevra Therapeutics in the 3rd quarter worth about $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Zevra Therapeutics during the third quarter worth approximately $33,000. Finally, Mystic Asset Management Inc. increased its position in shares of Zevra Therapeutics by 0.9% during the third quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company’s stock worth $3,899,000 after acquiring an additional 3,270 shares during the period. Institutional investors own 35.03% of the company’s stock.

Insider Buying and Selling at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. This trade represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the sale, the director directly owned 1,800 shares of the company’s stock, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.70% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.